All Pathways
Emergency MedicineEmergency

Anaphylaxis Management (GA²LEN International Consensus 2024)

Anaphylaxis Management (GA²LEN International Consensus 2024): Suspected Anaphylaxis → Anaphylaxis Criteria Met? → ⚡ EPINEPHRINE IM - FIRST LINE → Positi...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected Anaphylaxis

    Acute onset of multisystem involvement after exposure

    1. Decision

      Anaphylaxis Criteria Met?

      Clinical diagnosis - do not delay for labs

      • CRITERION 1: Skin + respiratory OR cardiovascular compromise
      • CRITERION 2: ≥2 systems after likely allergen: skin, respiratory, GI, cardiovascular
      • CRITERION 3: Hypotension after KNOWN allergen
      • Skin signs may be absent in 10-20% of cases
      1. Action

        ⚡ EPINEPHRINE IM - FIRST LINE

        Anterolateral thigh - DO NOT DELAY

        • Adult: 0.3-0.5 mg IM (1:1000 = 1mg/mL)
        • Child: 0.01 mg/kg IM (max 0.3mg)
        • Auto-injector: 0.3mg (>25kg) or 0.15mg (<25kg)
        • May repeat q5-15 min if needed
        • THERE IS NO CONTRAINDICATION IN ANAPHYLAXIS
        1. Action

          Position Patient

          Supine with legs elevated (if tolerated)

          • Trendelenburg if hypotensive
          • Sitting if respiratory distress
          • Left lateral decubitus if pregnant
          • DO NOT sit/stand up suddenly
          1. Decision

            Response to Epinephrine?

            Reassess within 5-15 minutes

            • Improvement in BP, breathing, symptoms
            • If no response, repeat epinephrine
            • After 2-3 doses, consider IV epinephrine
            1. Action

              Repeat Epinephrine IM

              May repeat q5-15 min x 2-3 doses

              • Same dose as initial
              • Different injection site preferred
              • Continue until response or IV access
              1. Decision

                Refractory to IM Epinephrine?

                After 2-3 IM doses, consider IV epinephrine

                1. Warning

                  IV Epinephrine Infusion

                  For refractory anaphylaxis ONLY - requires monitoring

                  • Dilute: 1mg in 100mL NS (10 mcg/mL)
                  • Start: 1-4 mcg/min, titrate to effect
                  • Requires cardiac monitoring
                  • ICU setting preferred
                  • Consider glucagon if on beta-blockers
                  1. Outcome

                    ICU Admission

                    Refractory or severe - ongoing monitoring

                2. Action

                  Observation Period

                  Monitor for biphasic reaction

                  • Minimum 4-6 hours for mild reactions
                  • 8-12 hours for moderate-severe
                  • 24 hours if prior biphasic reaction
                  • Biphasic occurs in 1-20% of cases
                  1. Action

                    Consider Labs

                    Do NOT delay treatment for labs

                    • Serum tryptase: 15min-3hr after onset
                    • Repeat at 24hr and baseline (2 weeks)
                    • Helps confirm diagnosis retrospectively
                    • May identify mastocytosis
                    1. Action

                      Discharge Planning

                      Patient education and follow-up

                      • Prescribe epinephrine auto-injector (2 devices)
                      • Teach auto-injector technique
                      • Written anaphylaxis action plan
                      • Referral to allergist
                      • MedicAlert bracelet recommendation
                      • Return immediately if symptoms recur
                      1. Outcome

                        Resolved

                        Symptoms controlled, safe for discharge

            2. Action

              Adjunct Therapies

              AFTER epinephrine - never delay epinephrine for these

              • IV fluids: NS bolus 1-2L (adults), 20mL/kg (peds)
              • Oxygen: High-flow, maintain SpO2 >94%
              • Albuterol: For bronchospasm not responsive to epi
              • Antihistamines: H1 (diphenhydramine) + H2 (famotidine)
              • Corticosteroids: May reduce biphasic reactions (evidence limited)
        2. Action

          Call for Help

          Activate emergency response/code team

          • Call resuscitation team
          • Note time of onset
          • Identify potential trigger
          • Prepare for escalation
        3. Action

          Remove Trigger

          If identifiable and safe to do so

          • Stop IV medications/contrast
          • Remove stinger (any method)
          • DO NOT delay epinephrine to remove trigger
      2. Action

        Consider Other Diagnoses

        Vasovagal, anxiety, other causes

        • Vasovagal syncope (pallor, bradycardia)
        • Panic attack (no objective signs)
        • Vocal cord dysfunction
        • Mastocytosis/mast cell activation
        • Hereditary angioedema (no urticaria)

Guideline Source

GA²LEN/EAACI Anaphylaxis Guidelines 2024: Acute Management and Care

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Epinephrine is the ONLY first-line treatment - never delay for other interventions
  • IM epinephrine is preferred in most settings over IV
  • Beta-blocker patients may have refractory anaphylaxis requiring glucagon
  • Biphasic reactions can occur up to 72 hours - discharge education critical
  • Does not cover allergen-specific immunotherapy protocols

Applicable Regions

USEUInternational

EU: Multiple auto-injector brands available with varying doses

US: Auto-injector dosing: EpiPen 0.3mg adults, 0.15mg pediatric

International: IM adrenaline 1:1000 (1mg/mL) is standard; some areas may only have IV formulations

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Anaphylaxis Management (GA²LEN International Consensus 2024)?

The Anaphylaxis Management (GA²LEN International Consensus 2024) is a emergency clinical algorithm for Emergency Medicine. It provides a structured decision tree to guide clinical decision-making, based on GA²LEN/EAACI Anaphylaxis Guidelines 2024: Acute Management and Care.

What guideline is the Anaphylaxis Management (GA²LEN International Consensus 2024) based on?

This algorithm is based on GA²LEN/EAACI Anaphylaxis Guidelines 2024: Acute Management and Care (DOI: 10.1111/all.16321).

What are the limitations of the Anaphylaxis Management (GA²LEN International Consensus 2024)?

Known limitations include: Epinephrine is the ONLY first-line treatment - never delay for other interventions; IM epinephrine is preferred in most settings over IV; Beta-blocker patients may have refractory anaphylaxis requiring glucagon; Biphasic reactions can occur up to 72 hours - discharge education critical; Does not cover allergen-specific immunotherapy protocols. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Anaphylaxis Management (GA²LEN International Consensus 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free